PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.

Safe dividend-paying income stocks trading under $30 are passive income home runs. Stocks trading under the $30 level offer Boomers a larger share count when they buy. With the geopolitical ...

Pfizer is undervalued as markets fixate on its patent cliff, overlooking strong cash flows, pipeline upside, and a 7% yield.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy. On June 17, Wolfe Research initiated ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

Vyndaqel’s gathering momentum – coupled with a 25% increase in sales of Pfizer’s breast cancer therapy Ibrance (palbociclib) to $1.28 billion – helped Pfizer post better-than-expected ...

However, amid the broader macro uncertainty, the drug and biotech sector seems to have recovered in the past month, backed by ...

PFE lags the market as COVID sales drop and patent losses loom, but new drugs and cost cuts may fuel a comeback.

The advent of ATTR-specific drugs, though pricey, is enabling better survival in these overlapping diseases, researchers say.

NICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has left the door open for negotiations if the pharma decides to drop its price.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy. On June 17, Wolfe Research initiated coverage of the stock with an ‘Outperform’ rating and a $49 price target.

The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF. - Part 6 ...